gms | German Medical Science

21st Annual Meeting of the German Retina Society and 8th Symposium of the International Society of Ocular Trauma (ISOT)

German Retina Society
International Society of Ocular Trauma

19.06. - 22.06.2008, Würzburg

Combined Intravitreal Bevacizumab and Triamcinolone for Exudative Age-Related Macular Degeneration

Meeting Abstract

  • Frank C. Schlichtenbrede - Mannheim/Germany
  • J.B. Jonas - Mannheim/Germany
  • T. Libondi - Mannheim/Germany
  • L. Golubkina - Mannheim/Germany
  • U.H. Spandau - Mannheim/Germany
  • F. Rensch - Mannheim/Germany

Retinologische Gesellschaft. International Society of Ocular Trauma. 21. Jahrestagung der Retinologischen Gesellschaft gemeinsam mit dem 8. Symposium der International Society of Ocular Trauma. Würzburg, 19.-22.06.2008. Düsseldorf: German Medical Science GMS Publishing House; 2008. DocISOTRG2008V117

The electronic version of this article is the complete one and can be found online at:

Published: June 18, 2008

© 2008 Schlichtenbrede et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.



Purpose: To report on the combined application of intravitreal bevacizumab with triamcinolone acetonide for treatment of exudative age-related macular degeneration.

Design: Clinical interventional case-series.

Methods: The study included 14 patients (14 eyes) with exudative age-related macular degeneration who had previously received 3.7 ± 1.9 mono-injections of bevacizumab (1.5 mg) without improvement in visual acuity or reduction in macular exudation. All patients underwent a combined intravitreal injection of bevacizumab (1.5 mg) and triamcinolone acetonide (about 20 mg). Main outcome measures were visual acuity and macular thickness as determined by optical coherence tomography. All patients were re-examined at 2 to 3 months after the intervention.

Results: Visual acuity improved significantly (P=0.008) from 0.81±0.43 logMAR prior to the combined injection to 0.67±0.41 log MAR. An improvement by at least 1 Snellen line was found for 10 (71%) subjects, an increase by at least 2 lines for 5 (36%) subjects, and an improvement of 3 or more lines for 1 (7%) subject. One patient (7%) lost one line. The central retinal thickness decreased significantly from 255 ± 59 µm to 224 ± 45 µm (P=0.03).

Conclusions: The combined intravitreal application of bevacizumab and triamcinolone may be helpful for the treatment of exudative age-related macular degeneration if previous intravitreal bevacizumab mono-injections failed to improve vision and reduce macular edema.